Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000638950 | SCV000760507 | likely benign | Familial melanoma | 2024-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002424414 | SCV002744233 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-15 | criteria provided, single submitter | clinical testing | The c.267C>T variant (also known as p.G89G), located in coding exon 2 of the CDKN2A gene, results from a C to T substitution at nucleotide position 267. This nucleotide substitution does not change the at codon 89. Of note, this alteration is also known as c.310C>T (p.L104F) in the p14(ARF) isoform and results from a C to T substitution at nucleotide position 310. The evidence for this gene-disease relationship is limited; therefore, the association of this alteration in the p14ARF isoform with melanoma-pancreatic cancer syndrome is unknown; however, the association of this alteration in the p16 isoform with melanoma-pancreatic cancer syndrome is unlikely. |